Management Articles

Bariatric surgery is an efficient method ? to achieve significant weight loss for NASH/NAFLD, learn more from our management articles.

European NAFLD guidelines: limitations when applied to T2D patients

G. Besutti et al. aimed to evaluate the feasibility and efficiency of a guidelines-compliant NAFLD assessment algorithm in patients with newly diagnosed type 2 diabetes. Consecutive patients newly diagnosed with T2D without coexisting liver disease or excessive alcohol consumption were enrolled. They were stratified...
Read MoreEuropean NAFLD guidelines: limitations when applied to T2D patients

NAFLD/NASH-related liver fibrosis: mechanisms, treatment, and prevention

NAFLD or NASH are nowadays the leading causes of hepatic fibrosis worldwide. In their review, F. Tacke (Charité University Medicine, Berlin, Germany) and R. Weiskirchen (RWTH University Hospital, Aachen, Germany) discuss recent advances in antifibrotic prevention and therapy....
Read MoreNAFLD/NASH-related liver fibrosis: mechanisms, treatment, and prevention

Immunotherapy-treated HCC: NASH limits anti-tumour surveillance

Immunotherapy has been approved for treating hepatocellular carcinoma (HCC), but biomarker-based stratification of patients for optimal response to therapy is an unmet need. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) did not lead...
Read MoreImmunotherapy-treated HCC: NASH limits anti-tumour surveillance

Management of NAFLD: a review

As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH.
Anti-inflammatory, anti-fibrotic agents and metabolism modulators...
Read MoreManagement of NAFLD: a review

Is Europe ready to meet the challenge of fatty liver disease?

NAFLD is closely associated with obesity, metabolic syndrome, and diabetes. NAFLD can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures. NAFLD preparedness means having adequate policies and civil society...
Read MoreIs Europe ready to meet the challenge of fatty liver disease?

NAFLD: a year in review

he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Read MoreNAFLD: a year in review

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Nowadays, dramatic changes in the lifestyle and diet of the global population are causing the prevalence of NAFLD increasing rapidly, in parallel with that of obesity and diabetes. Previous studies found an inverse relationship between physical activity and the risk of NAFLD. However, clinical trials...
Read MorePhysical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.